{
  "docId": "019de073-7b6a-72bb-8d98-812d56d63617",
  "docSlug": "f8b2787992eb3375620f74057447d0c9",
  "documentTitle": "Aravive | Investor Presentation Deck | 39 slides",
  "authorId": "aravive",
  "authorName": "Aravive",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-09-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 29,
  "pageCount": 39,
  "prevPage": 28,
  "nextPage": 30,
  "slideType": "appendix_methodology",
  "function": "plan_implementation",
  "density": "balanced",
  "nDataPoints": 4,
  "notes": "The slide outlines a standard clinical trial schema with a dose-finding/safety phase followed by a randomized efficacy phase.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-7b6a-72bb-8d98-812d56d63617/29",
  "deckHref": "/decks/019de073-7b6a-72bb-8d98-812d56d63617",
  "deckJsonHref": "/decks/019de073-7b6a-72bb-8d98-812d56d63617.json",
  "deckAnchorHref": "/decks/019de073-7b6a-72bb-8d98-812d56d63617#slide-29",
  "components": [
    {
      "bbox": {
        "h": 0.4,
        "w": 0.7,
        "x": 0.15,
        "y": 0.4
      },
      "kind": "diagram",
      "text": "Phase 1b to Phase 2 trial flow",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "edcbe552-305e-4a08-90bb-71d248fb52fd",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.2,
        "x": 0.4,
        "y": 0.75
      },
      "kind": "paragraph",
      "text": "Initiation of P2 will be based on clinical activity in Ph1b",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3927bd62-229b-4f99-a6cf-52c317fe623e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.85,
        "x": 0.08,
        "y": 0.18
      },
      "kind": "paragraph",
      "text": "P1b Population: Patients (N~20) with advanced or metastatic pancreatic adenocarcinoma eligible to receive gemcitabine + nab-paclitaxel (Abraxane®) as first-line treatment",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f066ec1b-bb90-49f4-9f99-70b4eb477b5c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "Batiraxcept + Gemcitabine + nab-Paclitaxel Phase 1b/2 Trial Design in 1L Pancreatic Adenocarcinoma (NCT04983407)",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1d5f36aa-2024-4225-8b89-f9d29156b697",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Process flow",
      "slug": "process-flow",
      "agent": null,
      "layer": "slide",
      "matchId": "c0c6e76a-4efb-4571-8840-baeafbcdfe88",
      "evidence": "diagram/process: Phase 1b to Phase 2 trial flow",
      "confidence": 0.8
    }
  ],
  "frameworks": [
    {
      "name": "clinical-trial-design",
      "slug": null,
      "matchId": "1f0f6543-9bcc-4dfc-9cd7-dd6558c74b0a",
      "evidence": "Standardized representation of patient cohorts and treatment arms in clinical research.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}